TXMD•benzinga•
Looking Into TherapeuticsMD's Return On Capital Employed
Summary
According to Benzinga Pro, during Q2, TherapeuticsMD (NASDAQ:TXMD) earned $112.28 million, a 329.05% increase from the preceding quarter. TherapeuticsMD also posted a total of $28.56 million in sales, a 47.73% increase since Q1.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 9, 2022 by benzinga